Indian cancer monoclonal antibodies market is estimated to grow at a CAGR of 12.5% during the forecast period. A significant rise in cancer incidences has been resulting in an increasing demand for monoclonal antibodies therapies in the country. As per the World Health Organization (WHO), in 2018, nearly 1.1 million new cancer incidences were reported in the country. In 2018, breast cancer accounted for 14.0%, lip, oral cavity (10.4%), cervix uteri (8.4%), lung (5.9%), stomach (5.0%), and other cancers (56.4%) of all new cancer incidences in the country. This leads to increasing demand for monoclonal antibody for cancer therapeutics which has shown to be more beneficial against some cancers compared to others. Some monoclonal antibodies used for cancer treatment are known as targeted therapy as they have a particular target on a cancer cell that intends to discover, attach to, and attack. However, some monoclonal antibodies work as immunotherapy as they support to make the response of the immune system better which in turn, supports the body to discover and attack cancer cells more potentially. 

Visit for Global Cancer Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market

Indian cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Naked monoclonal antibodies are the most common form of antibodies used for the treatment of cancer. Most naked monoclonal antibodies bind to antigens that are normally multiple on the surface of cancer cells compared to healthy cells. The increasing number of biosimilars of naked monoclonal antibodies is further accelerating market growth. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others.

Some key players in the market include AstraZeneca plc, Biocon Ltd., F. Hoffman-La Roche AG, Cadila Pharmaceuticals Ltd., and Dr. Reddy’s Laboratories, Inc. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in July 2020, Cadila Pharmaceuticals Ltd. declared the introduction of biosimilar Rituximab in India. It is indicated for the treatment of rheumatoid arthritis and blood cancer launched within the brand name Ritucad. It is used to treat Non-Hodgkin’s lymphoma (a type of blood-related cancer). According to the company, over 28,000 new cases of Lymphoma are reported each year in India. This launch will increase the accessibility of cancer treatment in the country. 

Research Methodology

The market study of Indian cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Indian Cancer Monoclonal Antibodies Market Research and Analysis by Type
2. Indian Cancer Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the Indian cancer monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Indian cancer monoclonal antibodies market.
• Insights about market determinants which are stimulating Indian cancer monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.